[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112018000635A2 - compostos aza substituídos como inibidores irak-4 - Google Patents

compostos aza substituídos como inibidores irak-4

Info

Publication number
BR112018000635A2
BR112018000635A2 BR112018000635A BR112018000635A BR112018000635A2 BR 112018000635 A2 BR112018000635 A2 BR 112018000635A2 BR 112018000635 A BR112018000635 A BR 112018000635A BR 112018000635 A BR112018000635 A BR 112018000635A BR 112018000635 A2 BR112018000635 A2 BR 112018000635A2
Authority
BR
Brazil
Prior art keywords
irak
inhibitors
compounds substituted
aza compounds
aza
Prior art date
Application number
BR112018000635A
Other languages
English (en)
Inventor
Gary Bock Mark
Mukherjee Subhendu
Samajdar Susanta
Rao Gummadi Venkateshwar
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of BR112018000635A2 publication Critical patent/BR112018000635A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

a presente invenção provê compostos aza substituídos de fórmula (i) ou (ii) e seus sais farmaceuticamente aceitáveis e seu uso para inibir irak-4 e/ou para o tratamento de doenças ou distúrbios induzidos por irak-4.
BR112018000635A 2015-07-15 2016-07-15 compostos aza substituídos como inibidores irak-4 BR112018000635A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3631CH2015 2015-07-15
IN3632CH2015 2015-07-15
PCT/IB2016/054229 WO2017009806A1 (en) 2015-07-15 2016-07-15 Substituted aza compounds as irak-4 inhibitors

Publications (1)

Publication Number Publication Date
BR112018000635A2 true BR112018000635A2 (pt) 2018-09-18

Family

ID=57757045

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000635A BR112018000635A2 (pt) 2015-07-15 2016-07-15 compostos aza substituídos como inibidores irak-4

Country Status (14)

Country Link
US (1) US20180208605A1 (pt)
EP (1) EP3322409A4 (pt)
JP (1) JP2018524365A (pt)
KR (1) KR20180026537A (pt)
CN (1) CN108024971A (pt)
AU (1) AU2016293446A1 (pt)
BR (1) BR112018000635A2 (pt)
CA (1) CA2992408A1 (pt)
EA (1) EA201890308A1 (pt)
HK (1) HK1249435A1 (pt)
IL (1) IL256581A (pt)
MX (1) MX2018000396A (pt)
PH (1) PH12018500041A1 (pt)
WO (1) WO2017009806A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038748B1 (ru) 2014-01-13 2021-10-14 Ориджин Дискавери Текнолоджиз Лимитед Способ получения бициклических гетероциклических производных
CU20180006A7 (es) * 2015-07-15 2018-06-05 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de irak-4
KR102507967B1 (ko) 2016-09-09 2023-03-09 인사이트 코포레이션 Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
AR109595A1 (es) 2016-09-09 2018-12-26 Incyte Corp Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
CN109890829B (zh) 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
MX2019011158A (es) 2017-03-31 2019-10-17 Aurigene Discovery Tech Ltd Compuestos y composiciones para tratar trastornos hematologicos.
JP2020516672A (ja) * 2017-04-18 2020-06-11 セルジーン クオンティセル リサーチ，インク． 治療用化合物
RS65838B1 (sr) * 2017-07-28 2024-09-30 Takeda Pharmaceuticals Co Tyk2 inhibitori i njihova upotreba
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
BR112020008214A2 (pt) 2017-10-31 2020-10-27 Curis, Inc. compostos e composições para tratar distúrbios hematológicos
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
HUE059624T2 (hu) 2018-02-20 2022-11-28 Incyte Corp N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
CR20220097A (es) 2019-08-06 2022-06-01 Incyte Corp Formas sólidas de un inhibidor de hpk1
WO2021066559A1 (en) * 2019-10-02 2021-04-08 Kainos Medicine, Inc. N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
BR112022019987A2 (pt) 2020-04-07 2022-11-22 Bayer Ag Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas
WO2021222366A1 (en) * 2020-04-28 2021-11-04 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
EP4225742A4 (en) 2020-10-05 2024-11-06 Enliven Inc 5- 6-AZAINDOL COMPOUNDS FOR INHIBITING BCR-ABL TYROSINE KINASES
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
WO2022135338A1 (zh) * 2020-12-25 2022-06-30 南京明德新药研发有限公司 酰胺噁唑类化合物
KR20240004476A (ko) * 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
TW202339738A (zh) 2022-01-31 2023-10-16 美商凱麥拉醫療公司 Irak降解物及其用途
MX2024009843A (es) 2022-02-14 2024-08-22 Astrazeneca Ab Inhibidores de irak4.
WO2023201272A1 (en) 2022-04-12 2023-10-19 Genzyme Corporation Use of irak4 modulators for gene therapy
WO2023227703A1 (en) 2022-05-26 2023-11-30 Astrazeneca Ab Solid forms of heterocyclylamides as irak4 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
MX2007007226A (es) * 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
EP1674467A1 (en) * 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
WO2007121154A2 (en) * 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
EP2640708A1 (en) * 2010-11-19 2013-09-25 Ligand Pharmaceuticals Inc. Heterocycle amines and uses thereof
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
KR101385603B1 (ko) * 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
EA038748B1 (ru) * 2014-01-13 2021-10-14 Ориджин Дискавери Текнолоджиз Лимитед Способ получения бициклических гетероциклических производных

Also Published As

Publication number Publication date
CN108024971A (zh) 2018-05-11
PH12018500041A1 (en) 2018-07-09
EA201890308A1 (ru) 2018-08-31
WO2017009806A1 (en) 2017-01-19
US20180208605A1 (en) 2018-07-26
EP3322409A1 (en) 2018-05-23
EP3322409A4 (en) 2019-07-24
CA2992408A1 (en) 2017-01-19
KR20180026537A (ko) 2018-03-12
IL256581A (en) 2018-02-28
HK1249435A1 (zh) 2018-11-02
MX2018000396A (es) 2018-05-02
JP2018524365A (ja) 2018-08-30
AU2016293446A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
BR112018000635A2 (pt) compostos aza substituídos como inibidores irak-4
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
BR112014027236A2 (pt) pirrolidinas substituídas como um fator inibidor de xia para o tratamento de doenças tromboembolíticas
DOP2016000173A (es) Heteroarilos y usos de estos
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112017013936A2 (pt) inibidores de bace1 seletivos.
BR112017002942A2 (pt) compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
BR112016024533A8 (pt) derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112018067922A2 (pt) compostos antibacterianos e seus usos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
UY36081A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112019008415A2 (pt) composto de piridona e inibidor de c-met, composição farmacêutica e uso dos mesmos
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017005324A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]